(VIANEWS) – Shares of TherapeuticsMD (NASDAQ: TXMD) dropped by a staggering 28.51% in 21 sessions from $4.91 at 2023-03-01, to $3.51 at 11:10 EST on Thursday, after five successive sessions in a row of losses. NASDAQ is falling 0.11% to $11,421.11, after three successive sessions in a row of gains.
TherapeuticsMD’s last close was $3.65, 84.13% below its 52-week high of $23.00.
About TherapeuticsMD
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Earnings Per Share
As for profitability, TherapeuticsMD has a trailing twelve months EPS of $-0.666.
Moving Average
TherapeuticsMD’s worth is way under its 50-day moving average of $5.20 and way below its 200-day moving average of $6.80.
Revenue Growth
Year-on-year quarterly revenue growth declined by 17.7%, now sitting on 87.49M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 77.8% and 68.2%, respectively.
More news about TherapeuticsMD (TXMD).
